Press coverage about Tenax Therapeutics (NASDAQ:TENX) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tenax Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 45.4790632073831 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Separately, ValuEngine upgraded shares of Tenax Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 27th.
Shares of Tenax Therapeutics (NASDAQ:TENX) traded up $0.31 during midday trading on Friday, hitting $7.63. 180,167 shares of the company traded hands, compared to its average volume of 520,416. Tenax Therapeutics has a one year low of $4.41 and a one year high of $15.88. The stock has a market capitalization of $10.77, a PE ratio of -0.24 and a beta of 1.69.
Tenax Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure.
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.